Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases
Launched by KANTONSSPITAL WINTERTHUR KSW · Jun 1, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a type of treatment called stereotactic body radiation therapy (SBRT) for patients with pain caused by bone metastases, which are cancer cells that have spread to the bones. The researchers want to find out if giving this treatment in three sessions is just as effective as the current method, which involves five sessions, in helping to reduce pain after three months.
To participate in this study, you must be at least 18 years old and have a confirmed diagnosis of cancer with bone metastases that is causing pain. You also need to be willing to provide your consent to join the trial. However, some individuals cannot join, such as pregnant or breastfeeding women, those with certain previous treatments, or those who may have health issues that prevent them from following the study procedures. If you join the trial, you can expect to receive radiation treatment over a few days, and the goal is to help manage your pain more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Personally signed and dated written informed consent,
- • Histological diagnosis of malignancy,
- • Histologically or radiologically diagnosed bone metastasis,
- • Age ≥ 18 years
- • Pain or under pain control medication
- Exclusion Criteria:
- • Pregnant or lactating women,
- • Women of childbearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment,
- • Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.,
- • Prior radiotherapy to the intended treatment site,
- • Lesions \> 5cm in maximum diameter,
- • Prior treatment with radioactive isotopes within 30 days of randomisation,
- • Spinal column, hands, feet, or head as intended treatment site,- Fracture at the intended treatment site,
- • Surgery required or previous surgery at the intended treatment site
- • Instability of the intended treatment site.
About Kantonsspital Winterthur Ksw
Kantonsspital Winterthur (KSW) is a leading academic hospital located in Winterthur, Switzerland, dedicated to providing high-quality patient care and advancing medical research. As a prominent clinical trial sponsor, KSW engages in innovative studies aimed at improving healthcare outcomes across various medical disciplines. The institution is committed to fostering collaboration between healthcare professionals and researchers, ensuring adherence to rigorous ethical standards and regulatory compliance. With state-of-the-art facilities and a multidisciplinary team of experts, KSW plays a pivotal role in the development of new therapies and treatment protocols that enhance patient care and contribute to the broader scientific community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Winterthur, , Switzerland
Winterthur, Kanton Zürich, Switzerland
Patients applied
Trial Officials
Robert Foerster, MD
Principal Investigator
Kantonsspital Winterthur KSW
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials